Home

Our Technology

Innovative Chemistry
Transformative Therapies

FDA “Fast Track” and “Breakthrough Therapy” designations received. 

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.

Investment

Long Term
Opportunity

Ensysce Biosciences Accelerates PF614-MPAR-102 Study

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 Read More
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach Read More
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs Read More
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 Read More
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PhD

Chief Executive Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt, PhD

Chief Medical Officer.

Jeffrey Millard, PhD

Chief Operating Officer

Geoff Birkett

Chief Commercial Officer

Linda Pestano, PhD

Chief Development Officer